#Neutralization, effector function and immune #imprinting of #Omicron #variants, Nature: https://www.nature.com/articles/s41586-023-06487-6 #research #immunity #SARS_CoV_2
#neutralization #imprinting #omicron #variants #research #immunity #SARS_COV_2
Tyson GB, Jones S, Logan N, McDonald M, Marshall L, Murcia PR, et al. #SARS-CoV-2 #seroprevalence and cross-variant #antibody #neutralization in #cats, #UK. Emerg Infect Dis. 2023 Jun [date cited]. https://doi.org/10.3201/eid2906.221755
#sars #seroprevalence #antibody #neutralization #cats #uk
#Beta #variant #COVID19 protein booster #vaccine elicits durable cross- #neutralization against SARS-CoV-2 variants in non-human primates https://www.nature.com/articles/s41467-023-36908-z
#beta #variant #COVID19 #vaccine #neutralization
#Neutralization of {#SARS-CoV-2 #Omicron} #BQ1, #BQ11, and #XBB {variants} with #RBD-Dimer
#Vaccines, NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2216233?query=TOC&cid=NEJM%20eToc,%20March%202,%202023%20DM2076332_NEJM_Non_Subscriber&bid=1438415850
#neutralization #sars #omicron #BQ1 #bq11 #xbb #rbd #vaccines
#Immunogenicity and #protection of a #variant nanoparticle #vaccine that confers broad #neutralization against #SARS-CoV-2 variants https://www.nature.com/articles/s41467-022-35606-6
#immunogenicity #protection #variant #vaccine #neutralization #sars
#Neutralization of #BA4–BA.5, #BA46, #BA275.2, #BQ11, and #XBB.1 with Bivalent #Vaccine, NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2214916?query=TOC&cid=NEJM%20eToc,%20January%2026,%202023%20DM1931502_NEJM_Non_Subscriber&bid=1379403247
#neutralization #BA4 #ba46 #ba275 #bq11 #xbb #vaccine
#Neutralization activity of #IgG #antibody in #COVID19‑convalescent #plasma against #SARS-CoV-2 variants https://www.nature.com/articles/s41598-023-28591-3
#neutralization #igg #antibody #COVID19 #plasma #sars
Substantial #Neutralization #Escape by #SARS-CoV-2 #Omicron #Variants #BQ11 and #XBB1, NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2214314?query=TOC&cid=NEJM%20eToc,%20January%2019,%202023%20DM1905150_NEJM_Non_Subscriber&bid=1364506926
#neutralization #escape #sars #omicron #variants #bq11 #xbb1
#Neutralization against #BA2752, #BQ11, and #XBB from #mRNA Bivalent #Booster, NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2214293?query=TOC&cid=NEJM%20eToc,%20December%2022,%202022%20DM1802081_NEJM_Non_Subscriber&bid=1327459834
#neutralization #ba2752 #bq11 #xbb #mrna #booster
#Neutralization of #Omicron Subvariant #BA275 after #Bivalent #Vaccination, NEJM: https://www.nejm.org/doi/full/10.1056/NEJMc2212772?query=TOC&cid=NEJM%20eToc,%20November%2024,%202022%20DM1695101_NEJM_Non_Subscriber&bid=1275987404
#neutralization #omicron #ba275 #bivalent #vaccination
Ju, B., Fan, Q., Wang, M. et al. #Antigenic sin of wild-type #SARS-CoV-2 #vaccine shapes poor cross- #neutralization of #BA4/5/2.75 #subvariants in #BA2 breakthrough infections. Nat Commun 13, 7120 (2022). https://doi.org/10.1038/s41467-022-34400-8
#antigenic #sars #vaccine #neutralization #BA4 #subvariants #ba2